Skip to main content
KROS filings

Corporate insider profile

Jean Jacques Bienaime Filing Activity

Latest reported as Director of Keros Therapeutics, Inc. (KROS).

Purchase filings
10
Reported companies
3
Net open-market value
$1,264,267
Latest transaction
Aug 17, 2026

Transaction history

Open-market Transactions

Open-market insider purchase and sale transactions
DateCompanyRoleTypeSharesPriceTotal value
Aug 17, 2026Keros Therapeutics, Inc. (KROS)DirectorOpen Market Purchase1,000$10.27$10,270
Aug 14, 2026Ascendis Pharma A/S (ASND)DirectorOpen Market Purchase2,000$246.33$492,654
Jul 15, 2026Keros Therapeutics, Inc. (KROS)DirectorOpen Market Purchase1,000$10.61$10,610